NasdaqGM - Delayed Quote USD
Ikena Oncology, Inc. (IKNA)
At close: November 21 at 4:00 PM EST
After hours: November 21 at 4:59 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mark Manfredi Ph.D. | President, CEO & Director | 810.69k | -- | 1971 |
| Dr. Jotin Marango M.D., Ph.D. | CFO & Head of Corporate Development | 577.12k | -- | 1979 |
| Ms. Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy & Communication | -- | -- | -- |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | -- | -- | 1970 |
| Mr. Bob Lally | Senior Vice President of Finance & Operations | -- | -- | -- |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | -- | -- | -- |
| Dr. Caroline Germa M.D., Ph.D. | Chief Medical Officer | -- | -- | 1972 |
| Mr. Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
Ikena Oncology, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 14
Description
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Corporate Governance
Ikena Oncology, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 7, 2024 at 1:30 PM UTC
Ikena Oncology, Inc. Earnings Date
Recent Events
Related Tickers
NXTC NextCure, Inc.
1.2900
-0.77%
AADI Aadi Bioscience, Inc.
2.2800
+2.70%
RLYB Rallybio Corporation
0.9886
-0.55%
VIGL Vigil Neuroscience, Inc.
3.0000
-1.64%
IPSC Century Therapeutics, Inc.
1.2400
-1.59%
KRON Kronos Bio, Inc.
0.8743
+1.66%
HLVX HilleVax, Inc.
1.8200
+1.68%
LYEL Lyell Immunopharma, Inc.
0.9166
-11.01%
OKUR OnKure Therapeutics, Inc.
15.99
-0.06%
MNOV MediciNova, Inc.
2.0000
+2.56%